Clinical trials: Pharmacotherapy
Microsatellite-stable Colorectal Cancer
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Columbia 2 is a Phase 2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX) alone and in combination with novel oncology therapies in adjuvant high-risk microsatellite-stable colorectal cancer
- Trial name
- NCT04145193
- Testing
- Standard of Care - mFOLFOX6, E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6, durvalumab and oleclumab
- Sponsor
- MedImmune LLC
Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Pharmacokinetic Study of Topical Phenylephrine
Pharmacokinetic Study of Topical Phenylephrine
- Trial name
- NCT07033845
- Testing
- Phenylephrine
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Applied Biology, Inc.
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
- Trial name
- NCT00430781
- Testing
- pazopanib (GW786034), lapatinib (GW572016)
- Where
- 63 sites in United States, Argentina and 11 more
- Volunteers
- 228 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Non-Small Cell Lung Cancer
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent…
- Trial name
- NCT01364012
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 17 sites in China
- Volunteers
- 276 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.
- Trial name
- COMPLEMENT (NCT00672919)
- Testing
- Pioglitazone
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Takeda
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined…
- Trial name
- NCT06051409
- Testing
- Olverembatinib, Investigator's choice of TKI
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 350 people
- Sponsor
- Ascentage Pharma Group Inc.
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Chemotherapy-induced Nausea and Vomiting
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting.
- Trial name
- NCT05199818
- Testing
- Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
- Where
- 13 sites in United States
- Volunteers
- 328 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer…
- Trial name
- NCT07803783
- Testing
- Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
HIV Infections
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine…
- Trial name
- NCT00002410
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 41 sites in United States, Puerto Rico
- Sponsor
- Dupont Merck
Prostate Cancer
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
- Trial name
- NCT00642018
- Testing
- docetaxel, LY2181308 sodium, Prednisone
- Where
- 17 sites in United States, Germany and 2 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Morquio Disease
Establishment of Human Cellular Disease Models for Morquio Disease
Establishment of human cellular disease models for Morquio disease for an individualized therapy development having the capacity to address both hepatic and neurologic forms of the disease
- Trial name
- IPSMORQUIO (NCT03872713)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
HER2-low Breast Cancer
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
- Trial name
- NCT06957886
- Testing
- BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
- Where
- 2 sites in China
- Volunteers
- 566 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody#SCT200#and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03874741
- Testing
- SCT200
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sinocelltech Ltd.
Colonic Neoplasms
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III colon cancer. Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS), safety (including long term…
- Trial name
- NCT00275210
- Testing
- Oxaliplatin (SR96669)
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,246 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns…
- Trial name
- FINN (NCT04794010)
- Where
- Germany
- Volunteers
- 825 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Trial name
- OlympiA (NCT02032823)
- Testing
- Olaparib
- Where
- 698 sites in United States, Argentina and 22 more
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
NSCLC
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
This study is multicenter, randomized, double-blinded, placebo-controlled Phase II study comparing vandetanib (300mg daily) plus best supportive care (BSC) to placebo plus BSC as maintenance treatment in patients with locally…
- Trial name
- NCT00777179
- Testing
- Vandetanib
- Where
- 5 sites in South Korea
- Volunteers
- 117 people
- Sponsor
- Genzyme, a Sanofi Company
HIV Infections
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
- Trial name
- NCT00002235
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.